featured
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy ± Sintilimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
Lancet 2024 May 30;[EPub Ahead of Print], X Liu, Y Zhang, KY Yang, N Zhang, F Jin, GR Zou, XD Zhu, FY Xie, XY Liang, WF Li, ZY He, NY Chen, WH Hu, HJ Wu, M Shi, GQ Zhou, YP Mao, R Guo, R Sun, J Huang, SQ Liang, WL Wu, Z Su, L Li, P Ai, YX He, J Zang, L Chen, L Lin, SH Huang, C Xu, JW Lv, YQ Li, SB Hong, YS Jie, H Li, SW Huang, YL Liang, YQ Wang, YL Peng, JH Zhu, SB Zang, SR Liu, QG Lin, HJ Li, L Tian, LZ Liu, HY Zhao, AH Lin, JB Li, N Liu, LL Tang, YP Chen, Y Sun, J MaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.